Neuroproteins-stroke

2019 Activity indicators

  • 4 national public projects: ISCIII, MINECO.
  • 2 private led projects.
  • 20 clinical led trials
  • 4 competitive HR contracts.
  • 20 publications
  • IF: 155.38.
  • Publications in D1: 4 (20%).
  • Publications in Q1-Q2: 16 (80%).
  • 2 supervised read thesis.
  • Public agency evaluators: 2 PIs.
  • Members of editorial committees: 1 PI.
  • 1 visitor received and 6 months' stay:
    • Madrid Autonomous University.
  • 1 patent family extended internationally in 11 countries that protects the use of steroidal nitrones in neurodegenerative diseases (PCT/ ES2014/070421), 6 of them were granted.
  • 1 patent granted (P201131338) that protects, at national level, quinoline nitrones with this purpose.

Milestones

  1. Publication of the important clinical trial conducted to determine pharmacological efficacy in cases of stroke of unknown origin: Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source. Diener HC, Sacco RL, Easton JD, Granger CB, Bernstein RA, Uchiyama S, Kreuzer J, Cronin L, Cotton D, Grauer C, Brueckmann M, Chernyatina M, Donnan G, Ferro JM, Grond M, Kallmünzer B, Krupinski J, Lee BC, Lemmens R, MASJUAN J, et al. N Engl J Med. 2019; 380:1906-1917. doi: 10.1056/ NEJMoa181395
  2. Publication of a potential drug for the treatment of ischemic stroke: New Quinolylnitrones for Stroke Therapy: Antioxidant and Neuroprotective ( Z)- N- tert-Butyl-1-(2-chloro-6-methoxyquinolin-3-yl) methanimine Oxide as a New Lead-Compound for Ischemic Stroke Treatment. Chioua M, MARTÍNEZALONSO E, Gonzalo-Gobernado R, Ayuso MI, ESCOBAR-PESO A, Infantes L, Hadjipavlou-Litina D, Montoya JJ, Montaner J, ALCÁZAR A, Marco-Contelles J. J Med Chem. 2019; 62:2184-2201. doi: 10.1021/acs. jmedchem.8b01987
  3. Publication of new findings on the vulnerability of the hippocampus: Characterisation of the Mechanisms Underlying the Special Sensitivity of the CA2 Hippocampal Area to Adenosine Receptor Antagonists. MUÑOZ MD, SOLÍS JM. Neuropharmacology. 2019;144:9-18. doi: 10.1016/j.neuropharm.2018.10.017.
  4. Publication of new advances in the treatment of patients with PD: Impact of Disease Duration in Effectiveness of Treatment with Levodopa-Carbidopa Intestinal Gel and Factors Leading to Discontinuation. REGIDOR I, et al. J Parkinsons Dis. 2019;9:173-182. doi: 10.3233/JPD-181324.
  5. PCT Patent Application number PCT/EP2019/077525: "New Quinolylnitron for the Treatment of Stroke". Entity Holder: FIBIO Hospital Universitario Ramón y Cajal.

Bibliometrics

  Articles Accum. FI Mean IF Articles Q1 or Q2 % in Q1 or Q2 Articles D1 % in D1
2015 8 26.13 3.27 45 64 12 17
2016 27 153.21 5.67 19 70 7 26
2017 15 47.70 3.18 13 87 1 7
2018 20 46,38 2.90 8 40 1 5
2019 20 153.38 9.59 16 80 4 20
  90 426.80 4.92 61 68 16 18

* Only original articles, editorials, guidelines & reviews

Networks and alliances

  • GEEC - Grupo de estudio de enfermedades cerebrovascular
  • Madrid Stroke Network Data
  • RETIC INVICTUS
  • Instituto de Salud Carlos III